Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-site Laboratory-based Diagnostic Accuracy and Feasibility Study of the Xpert MTB/XDR Assay for Detection of Isoniazid, Fluoroquinolone, Ethionamide and Second-line Injectable Anti-tuberculosis Drug Resistance

NCT04567368 is registered in ClinicalTrials.gov with Foundation for Innovative New Diagnostics, Switzerland as lead sponsor.

NCT NCT04567368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04567368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-site Laboratory-based Diagnostic Accuracy and Feasibility Study of the Xpert MTB/XDR Assay for Detection of Isoniazid, Fluoroquinolone, Ethionamide and Second-line Injectable Anti-tuberculosis Drug Resistance
Lead sponsor
Foundation for Innovative New Diagnostics, Switzerland
Phase
Observational
Overall status
Active, not recruiting
Start date
May 14, 2021
Completion date
December 30, 2024
Enrollment
753 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diagnoses disease, resistance bacterial, tuberculosis